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Abstract ISBT 128 is the global standard for the
identiﬁcation, labeling and information transfer of
human blood, cell, tissue and organ products across
international borders and disparate health care sys-
tems. The system has been designed and perfected
over almost two decades to ensure accuracy, safety
and efﬁciency for the beneﬁt of donors, patients and
health care workers worldwide. The use of the ISBT
128 standard has grown steadily since a blood bank in
Estonia ﬁrst implemented it in 1997. Today, more
than 3,500 facility identiﬁers for the use of ISBT 128
have been assigned to organizations in 67 countries
on six continents. The standard has been accepted by
a variety of international standard setting organiza-
tions and government regulators. It is managed by
ICCBBA, a not-for-proﬁt organization based in the
USA that is governed by an international volunteer
board of directors. Members of the Board of Direc-
tors represent the ﬁelds of practice affected by the
standard. Advisory groups comprising international
experts guide the ongoing development of the ISBT
128 standard to ensure it continues to meet the needs
of its users. While there is a cost associated with the
implementation and use of the standard, the clear
beneﬁts in terms of improved patient safety and
ability to meet regulatory traceability requirements
justify the costs.
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ISBT 128 is the international standard for the transfer
of information associated with transplantation and
transfusion. It provides:
• a globally unique donation numbering system
• internationally standardized product codes
• standard data structures for bar coding and
electronic data interchange
• standardized labeling
ISBT 128 is a standard; no data related to blood,
cellular therapy or tissue donations (apart from
details of facilities licensed to use the standard) are
maintained by ICCBBA, the organization that main-
tains the standard.
The name of the standard reﬂects its origins. A
working party of the International Society of Blood
Transfusion (ISBT) initially developed the standard.
Code 128 was the linear bar code symbology chosen
for use with the new standard.
Why standardize?
The international movement of cell and tissue
products is now commonplace. Such movement,
without associated standards for identiﬁcation,
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increase workload, compromise traceability, and can
lead to serious and potentially fatal patient harm.
Without globally unique donation identiﬁcation and
common terminology there is the risk of duplication
of identiﬁers and misidentiﬁcation of products result-
ing in the wrong graft being implanted. To overcome
this, importers may re-number and re-label imported
products; however, this is a process which is time
consuming and error prone. In addition, re-numbering
makes the traceability path more complex and less
reliable. The use of bar coding and computer control
is a well recognized means of reducing manual
transcription and identiﬁcation errors, but without
international standardization of the bar code repre-
sentation of critical information, these safety beneﬁts
are not available for imported products.
Global standardization of coding and labeling is
primarily a patient safety initiative. It permits the
international movement of tissues and cells in a
manner that eliminates the need for re-numbering,
ensures common understanding of product descrip-
tions, and supports computer control to reduce error.
It also helps to provide a more robust traceability path
and supports rapid alerts in the situation of adverse
events requiring product recall.
Since standardization and bar coding have many
advantages, it is not surprising that use of ISBT 128
has grown steadily over the years. The need for
international standardization is particularly important
for cellular therapy and tissue products since there is
a high likelihood that these products will be shipped
across international borders. The World Marrow
Donor Association (2008) indicated that 43.8% of
stem cell donations intended for unrelated recipients
were shipped internationally in 2008 and the percent
of international shipments has shown an upward
climb since 2002.
Recognizing this international transfer of biolog-
ical products, a WHO (2006) report stated ‘‘As this
globalization of cells and tissue transplantation
develops, the need for common product names and
deﬁnitions and for unique product identiﬁcation
becomes essential.’’ The commentary of WHO
(2008) Guiding Principle 10 states: ‘‘Internationally
agreed means of coding to identify tissues and cells
used in transplantation are essential for full
traceability.’’
A single coding system for blood, cells, tissues and
organs is also advantageous as noted in a European
Committee for Standardization report (CEN Work-
shop Agreement, CWA 15849, 2008):
A donor could have a varied donation history,
or a single donation event could result in
donated material falling under multiple legisla-
tion sectors. For instance, a deceased donor
could donate organs, tissues and cells in a single
donation event. This could be extended to other
legislated sectors such as tissue engineering,
utilization of embryonic stem cell lines and
other regenerative medicine uses.
In the future it is feasible that with technolog-
ical advances in regenerative medicine that the
interfaces between blood, tissues, cells and
organs may become less deﬁned.
It is similarly feasible that the legislative
framework may have to change to reﬂect
changes in what are now separate sectors
governed by discrete pieces of legislation. It is
conceivable that the legislative structure may
evolve to an umbrella framework in the future.
For these reasons it would be useful if the
coding system for all sectors had a common
background.
Because ISBT 128 provides for coding of blood,
cellular therapy and tissue products, and will be
extended to include organs, it is an ideal standard to
enable facilities to achieve this goal.
Standardization with ISBT 128:
• facilitates international shipment of products
because bar codes have the same meaning glob-
ally eliminating language barriers
• improves traceability because assigning globally
unique identiﬁers eliminates the need to renumber
units when products are received from outside a
local area
• improves safety because the receiving facility can
understand detailed product characteristics
regardless of the language on the label
• reduces costs because software developers do not
have to customize their products for each facility
• facilitates movement into newer technology data
transfer mechanisms such as two dimensional bar
codesandradiofrequencyidentiﬁcation(RFID)tags
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• improves safety and traceability by eliminating
error-prone keyboard entry of product information
• improves efﬁciency by allowing scanned entry of
products
The beginning
An early stimulus for ISBT 128 was the 1990–1991
Persian Gulf War when the military received blood
from different countries. They found duplication in
‘‘unique’’ identiﬁers as well as difﬁculty in reading
labels with different languages. Bar codes were
frequently present, but could not be interpreted
because a given bar code could have different mean-
ings depending on the source of the blood. The US
Department of Defense provided a report to the Blood
Products Advisory Committee (1997) that stated, ‘‘In
Desert Shield/Desert Storm the U.S. military con-
tracted with numerous civilian blood suppliers to ship
blood to the Persian Gulf. In theatre operations the
military found thousands of labeling mistakes. These
included: bar code substitution errors; absence or use
of un-standardized donation identiﬁcation start codes;
improper or incorrect start codes in FDA registration
number; general noncompliance with the 1985 label-
ing guidelines; and duplication of donation numbers.
All of this resulted in misidentiﬁcation of units,
requiring manual data entry and unit renumbering,
and increased opportunity for undetected error, and a
decrease in productivity.’’ It became apparent that
blood was an international resource and there was a
desperate need for a globally standardized system of
coding critical information.
As a result, the International Society of Blood
Transfusion (ISBT) charged its Working Party on
Automation and Data Processing (subsequently
renamed the Working Party on Information Technol-
ogy) with creating a standardized means of labeling
blood products so that identiﬁers were globally
unique and bar codes (as well as other means of
electronic information transfer) would have the same
meaning internationally. The ﬁrst version of the
standard they produced was formally approved by the
ISBT in 1994.
Almost immediately, tissue and cellular therapy
organizations recognized the applicability of the new
standard to their work. The Carolinas Cord Blood
Bank, Duke University began using ISBT 128 for
their products in 1997. The Tissue Services Depart-
ment of the National Blood Service in the United
Kingdom started using ISBT 128 donation identiﬁ-
cation numbers in 1997, and fully implemented ISBT
128 for tissues in 2003. Following the lead of these
organizations, other cellular therapy and tissue facil-
ities worldwide adopted ISBT 128 for labeling and
coding of their products.
ICCBBA
TheISBTWorkingPartyrecognizedthatamechanism
would be required by which the standard could be
maintained and developed to meet future needs of the
transfusion community. ISBT, in collaboration with
the AABB and American Red Cross, agreed to form
the International Council for Commonality in Blood
Bank Automation (ICCBBA) to manage and develop
the standard, and in 1995, ICCBBA was incorporated
as a not-for-proﬁt organization in the USA.
ICCBBA is governed by an international volunteer
board of directors comprising leaders in the ﬁelds of
blood, cellular therapy and tissue banking. The Board
of Directors meets regularly through conference calls
and an annual face-to-face meeting.
ICCBBA is a tax exempt, nonproﬁt organization as
described in Section 501 (c) (3) of the US Internal
Revenue Code (Internal Revenue Service 2010).
These regulations stipulate that the organization
cannot be organized or operated for the beneﬁt of
private interests, and no part of the organization’s net
earnings may inure to the beneﬁt of any private
shareholder or individual (IRS.gov 2010). Within its
Articles of Association, ICCBBA is required to be
organized and operated exclusively for charitable,
scientiﬁc and educational purposes.
To ensure openness, ICCBBA publishes an Annual
Report on its website (www.iccbba.org) that is
available to the public. The report discloses IC-
CBBA’s income and expenditures, as well as its
balance sheet, and summarizes activities for the year.
From the most recent report (ICCBBA 2008), it can
be seen that ICCBBA is an efﬁcient organization that
Cell Tissue Bank (2010) 11:365–373 367
123operates with a small staff and has modest income
and expenditures.
The people behind the process
In its role of managing the ISBT 128 standard,
ICCBBA involves international experts in blood,
cellular therapy and tissue banking. These experts are
organized into Technical Advisory Groups (TAGs)
that meet regularly (both face-to-face and through
conference calls) to further develop and expand the
ISBT 128 standard ensuring that it continues to meet
the needs of its users. The vital role of these groups
cannot be overemphasized. It is only through the
involvement of such expert panels that ICCBBA can
be assured it has the knowledge base to anticipate the
needs of its users in ﬁelds where change is constant.
More than 150 experts participate in the ICCBBA
TAGs.
There are currently seven TAGs, as described in
Table 1. In addition to the membership described in
the table, each group may also invite liaisons from
professional associations and regulatory agencies to
attend its meetings. In order to make the process
transparent, other interested persons may attend
meetings as observers.
The output of the TAGs is reviewed by an
Editorial Board, comprising professionals with both
expertise in their ﬁelds and experience with ISBT 128
to ensure consistency, accuracy and practicality.
Finally, a small staff of eight people manages the
practical aspects of the standard ensuring such things
as: documents supporting the standard are written and
updated regularly, databases are updated frequently,
the communication link to its users (the ICCBBA
website) is well-maintained and ICCBBA itself is
managed in a stable and professional manner. A full
time, dedicated staff ensures that the needs of users
are always a priority.
Globally unique identiﬁers
A key beneﬁt of ISBT 128 is the assignment of
identiﬁers to products that are unique globally for
100 years. Each identiﬁer (Donation Identiﬁcation
Number or DIN) has three parts: (1) a ﬁve-character
Facility Identiﬁcation Number (FIN) assigned by
ICCBBA, (2) a two-character year and (3) a six-
character serial number assigned by the facility. (See
Fig. 1). These globally unique identiﬁers eliminate
the need to renumber products and thereby simplify
and strengthen the traceability process.
The name ‘‘Facility Identiﬁcation Number (FIN)’’
implies the identiﬁer is assigned to a facility, and in
fact this is the most common situation. However,
there is ﬂexibility in how the FINs may be assigned.
ICCBBA can also assign these identiﬁers to other
organizations such as a regional or national organi-
zation, a national health authority or a registry. These
organizations can, in turn, manage donation identiﬁ-
cation numbers.
If there are multiple formats for donation identi-
ﬁcation numbers, computer systems have to allow a
very large ﬁeld size to accommodate all possible
numbers. Moreover, systems cannot be programmed
to recognize improperly entered numbers (e.g., ones
with too many or too few characters). If all biological
products a facility receives have a single, standard-
ized format, computer software may be written to
ensure the proper number of characters are entered
similarly to the way in which software programs
recognize if an email address is not entered in the
correct format. While it is hoped that identiﬁcation
numbers would always be scanned into a computer
system, this is not always going to be the case. If the
entry of the number is made through a keyboard, it
becomes even more important for the computer
system to recognize if a number was entered in the
wrong format.
When manual systems are used, it is still important
to have a standard format so manual worksheets can
be designed to prompt the user to record the correct
number of characters.
As noted above, the importance of internationally
standardized unique identiﬁers was recognized in
both a WHO report (2006) and the US Department of
Defense report to the Blood Products Advisory
Committee (1997).
Product coding
The ISBT 128 product description code database
contains more than 7,000 product description codes.
Each product description (e.g., Hematopoietic Pro-
genitor Cell collected by apheresis, using citrate as an
368 Cell Tissue Bank (2010) 11:365–373
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assigned a ﬁve-character product description code.
There are three additional characters in each product
code: For cells and blood, there is a one-character
donation type (e.g., allogeneic or autologous) code
followed by a two-character division code. For
tissues, there is a three-character division code (See
Fig. 2).
The ﬁve-character product descriptions and codes
are maintained in a database (see Table 2 for an
excerpt) on the ICCBBA website and made available
to ICCBBA-licensed facilities.
Table 1 ICCBBA technical advisory groups
Group Focus Members
Americas Technical Advisory
Group (ATAG)
Blood Banking in North, South and
Central America
Expert users from hospitals and blood centers in North
and South America
Middle East and Europe
Technical Advisory Group
(MEETAG)
Blood Banking in Europe and the
Middle East
Representatives from countries in Europe and the
Middle East that have ICCBBA-registered facilities
Asia Paciﬁc Technical Advisory
Group (APTAG)
Blood Banking in Asia and the Paciﬁc
region (including Australia and New
Zealand)
Representatives from countries in Asia, Australia and
New Zealand that have ICCBBA-registered facilities
Cellular Therapy Coding and
Labeling Advisory Group
(CTCLAG)
International cellular therapy Representatives from:
AABB
Asia Paciﬁc Blood and Marrow Transplant (APBMT)
American Society for Blood and Marrow
Transplantation (ASBMT)
American Society for Apheresis (ASFA)
European Group for Blood and Marrow
Transplantation (EBMT)
Foundation for the Accreditation of Cellular Therapy
(FACT)
International Society of Blood Transfusion (ISBT)
International Society for Cellular Therapy (ISCT)
ISCT Europe
Joint Accreditation Committee of ISCT and EBMT
(JACIE)
National Marrow Donor Program (NMDP)
World Marrow Donor Association (WMDA)
Additional technical experts, selected for their
knowledge and experience, also sit on the committee
Europe Tissue Technical
Advisory Group (ETTAG)
European tissue Representatives from countries in Europe that have
ICCBBA-registered facilities or that have an interest
in ISBT 128
North America Tissue
Technical Advisory Group
(NATTAG)
North American tissue Expert users from tissue banks in North America
This committee is jointly sponsored by the American
Association of Tissue Banks (AATB) and ICCBBA.
Eye Bank Technical Advisory
Group (EBTAG)
International eye banking Representatives from:
Eye Bank Association of America (EBAA)
Eye Bank Association of Australia and New Zealand
(EBAANZ)
European Eye Bank Association (EEBA)
Pan American Association of Eye Banks [or the
Asociacion Pan-Americana de Bancos de Ojos
(APABO)]
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standard is its ﬂexibility. The level of detail that is
encoded into the electronically readable information
can vary. For example, for blood products each
anticoagulant (CPD, CPDA-1, CP2D, ACD-A, ACD-
B, Sodium Citrate or heparin) may be encoded into
electronically readable information.However it is also
possible to encode a blood product without specifying
the anticoagulant. This level of ﬂexibility has led to
over 6,700 blood product description codes. However,
the Cellular Therapy Coding and Labeling Advisory
Group (CTCLAG) chose to encode much less detail
into product description codes for cellular therapy
products.Here, simply encoding citrateand/or heparin
as the anticoagulant was considered an adequate level
of detail for electronic communication. The speciﬁc
anticoagulant may be detailed in other documentation
accompanying the product, but is not communicated
electronically.Thishasledtofarfewercellulartherapy
product description codes and hence less complexity.
Within tissue banking, the Europe Tissue Techni-
cal Advisory Group (ETTAG) and the North America
Tissue Technical Advisory Group (NATTAG) are
currently determining the level of detail needed for
tissue products in the future. The international Eye
Bank Technical Advisory Group is also in the process
of determining the level of detail appropriate for
electronic communication.
Within the constraints determined by the advisory
groups, the standard allows facilities to select the
product description codes that describe their products
at the level of detail most appropriate for the users of
their products.
ICCBBA-licensed facilities may request new
codes whenever they are needed through a simple
on-line request form. If such codes do not require any
new terminology, they are generally available within
4–6 weeks. If new terminology is needed, the request
is reviewed by the appropriate technical advisory
group to ensure consensus for the terminology chosen
and may take a little longer.
Managing change to the standard
Changes to the standard are required as new products
are developed. Changes are also frequently needed
when the ﬁrst facility within a country adopts the
standard. Such changes are carefully managed
through a transparent proposal process. Any user
can suggest changes. Suggestions are captured into
formal proposals which are reviewed by the TAG(s)
with the appropriate expertise. If approved by the
TAGs, the proposals are reviewed by the Editorial
Board and staff for consistency with the ISBT 128
standard and for backward compatibility. Once ﬁnal
approval is obtained, changes are published in
appropriate documents and made available to users.
Worldwide usage of ISBT 128
As of January 1, 2010, more than 3,500 facility
identiﬁers for the use of ISBT 128 had been assigned
to organizations in 67 countries (see Table 3) on six
continents. Not all facilities that are registered with
ICCBBA will have implemented ISBT 128 and
registration may be by blood, cellular therapy and/
or tissue facilities within a country.
Given the frequency with which cellular therapy
products are shipped across national borders, standard
setting organizations (AABB, FACT and JACIE)
were quick to see the beneﬁt of standardized termi-
nology. These cellular therapy standards organiza-
tions now require that ISBT 128 terminology be used
to label products (AABB 2009) (FACT/JACIE 2008).
This requirement came about very quickly once
CTCLAG reached consensus on terminology (Ash-
ford et al. 2007a, c, f) and provided guidance for
implementation (Ashford et al. 2007b, d, e). Long
term, it is expected that these organizations will
require full ISBT 128 labeling.
Representatives from international eye banking
associations and other interested parties have begun
W0000 10 123456  
Year  Facility 
Identification 
Number
Serial 
Number
Fig. 1 Donation identiﬁcation number
T0122000 
Divisions  Product 
Description 
Code 
Fig. 2 Tissue product code
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labeling to their products. As indicated in Table 1,
membership in this advisory group reﬂects a global
interest in use of the ISBT 128 standard for ocular
tissue.
Information access
ICCBBA makes available to the public most of its
documents through its website (www.iccbba.org).
These publicly available documents include:
• ISBT 128 Standard Technical Speciﬁcation (the
primary document for describing the standard)
• Standard Terminology for Blood, Cellular Ther-
apy and Tissue Product Descriptions
• Technical Bulletins of general interest
Additionally, educational and introductory docu-
ments are available to all who are interested. The
ICCBBA website provides a vast amount of infor-
mation and is a primary resource in implementing
ISBT 128.
Databases (product description codes and facili-
ties), as well as technical documents speciﬁc to the
implementation of the standard, are available on the
ICCBBA website to users from facilities that are
registered and licensed with ICCBBA and that have
requested a password to access this information. Both
the facility and product description code databases
are updated approximately 10 times per year as new
product description codes and facilities are added.
Fees
To best meet the needs of its users, the ISBT 128
standard must be maintained in a manner that is
stable, ﬂexible and responsive. It must be profession-
ally managed to ensure these needs are met. As is the
case for all services of high quality, there is an
associated cost.
ICCBBA charges a fee, which is published on its
website, for services that include the use of the ISBT
128 Standard and its supporting databases, access to
the full documentation set, provision of globally
unique facility identiﬁers, and helpdesk technical
support. The annual license fee is established by the
ICCBBA Board of Directors taking a number of
factors into consideration. Chief among these is
funding the annual cost of operations for supporting,
maintaining and administering the ongoing develop-
ment of the standard for the beneﬁt of all users.
Additional factors include the type of licensee
organization and the location of the organization.
Fees are reduced for countries in low and medium
development areas as deﬁned by the U.N.’s Human
Development Index (HDI).
ICCBBA operates a highly ﬂexible billing system
and can group facilities together for billing purposes.
Table 2 Excerpt from ICCBBA product code description database
Product description code Proddescription Code date
T0122 Cryopreserved VALVE, AORTIC 14 Feb 2001
Table 3 Countries with ICCBBA-registered facilities
Algeria
Argentina
Australia
Austria
Belarus
Belgium
Bosnia-Herzegovina
Botswana
Brazil
Canada
China
Columbia
Cote d’Ivoire
Croatia
Cyprus
Czech Republic
Denmark
Dominican Republic
Egypt
Estonia
Ethiopia
Finland
France
Germany
Greece
Honduras
Hungary
Iceland
India
Iran
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lithuania
Malaysia
Mexico
Moldova
Nigeria
Norway
Pakistan
Poland
Portugal
Qatar
Republic of China
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovenia
South Africa
South Korea
Spain
Sultanate of Oman
Sweden
Switzerland
Thailand
The Netherlands
Turkey
United Arab Emirates
United Kingdom
United States of America
Vietnam
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including payment by individual facility, payment by
a single administrative source for multiple facilities
(such as a Red Cross administrative center paying for
all Red Cross facilities in a country), and payment by
a national authority for all facilities in the country.
Future
The future of ISBT 128 will reﬂect the future of the
facilities it serves. Facilities in additional countries
will adopt ISBT 128 and have special needs. New
products will be developed. Especially in the area of
cellular therapy, some of these new products will be
challenging to deﬁne. Regenerative medicine will
blur the lines between cellular and tissue products.
ISBT 128 must meet these challenges and provide the
tools for coding and labeling a wide variety of new
biological products in a timely manner.
New TAGs with expertise in a variety of ﬁelds will
likely be needed. For example, Reproductive Medi-
cine is a ﬁeld where ICCBBA will likely need
additional expertise to ensure that ISBT 128 meets
the needs of coding and labeling these very special-
ized products. Organ transplant is clearly another area
where ISBT 128 can be of beneﬁt and expert panels
will need to be organized and supported.
With each new country that adopts ISBT 128, the
standard will also have to demonstrate its ﬂexibility
to be compatible with a wide variety of national
regulations for the labeling of biological products.
As with all things in life, success is about balance.
The future success of the ISBT 128 standard rests on
its on-going ability to achieve balance in—
• achieving standardization that ensures products
can cross international borders with labeling that
can be read and interpreted as intended while
providing the ﬂexibility to meet the global needs
for different languages and regulations
• attracting people with new expertise into its
TAGs while retaining professionals experienced
with the use ISBT 128
• encouraging creativity to meet future needs while
remembering lessons learned
• bringing in new ﬁelds such as organ transplant
while meeting the needs of ﬁelds already using
the standard
• being responsive to requests for change while
giving careful consideration to ensure changes are
wise
• offering high value for fees charged while having
adequate resources to meet the expanding needs
of high growth ﬁelds
Work on the ISBT 128 standard began almost two
decades ago. Since that time, many countries have
implemented it and shown that the standard is
capable of meeting the changing needs for coding
and labeling of biologics over the long term. In doing
so, the ISBT 128 standard has proven it is capable of
achieving the necessary balance to ensure continued
stability and growth.
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